Schorno Dean L 4

What Happened
Dean L. Schorno, Chief Financial Officer of Rigel Pharmaceuticals (RIGL), received an award of 20,636 restricted stock units (RSUs) reported on Feb 17, 2026. The Form 4 shows an acquisition code "A" for 20,636 shares at $0.00 (grant of RSUs), meaning no cash was paid and the units convert to common stock only upon vesting.

Key Details

• Transaction date: 2026-02-17 (reporting period 2026-02-17).
• Transaction type/code: Grant / Award (A).
• Units: 20,636 RSUs; reported price: $0.00 (typical for equity awards).
• Shares owned following transaction: The filing records an RSU grant (future vesting) rather than immediate share delivery; immediate change in beneficial ownership is not reported.
• Footnote: RSUs vest quarterly over three (3) years, with the first quarterly vesting on March 31, 2026.
• Timeliness: Filing shows the transaction and no late-filing flag is indicated in the provided details.

Context
RSUs are compensation that convert into company shares as they vest and are generally taxed when the shares are delivered. This filing documents a standard equity award to an executive rather than a market purchase or sale; it does not by itself signal a buy or sell action in the open market.